论文部分内容阅读
目的:探讨恩替卡韦对乙型肝炎病毒(HBV)DNA阳性肺结核患者肝功能干预作用。方法:将165例HBV DNA阳性肺结核患者随机分成治疗组81例和对照组85例。观察2组病例肝损发生率、发生时间、损伤程度,并将所得数据作统计学处理。结果:治疗组肝损发生率低(18.5%),出现时间晚(30~150)d,肝损程度轻,恢复快(17±3.8)d,完成抗结核治疗时间相对较短(210±16.3)d,与对照组相比差异有显著性(P<0.01)。结论:恩替卡韦对HBV DNA阳性肺结核患者肝功能有明显干预作用,可显著降低结核药物对此类患者的肝损伤。
Objective: To investigate the effect of entecavir on liver function in patients with hepatitis B virus DNA positive pulmonary tuberculosis. Methods: One hundred and sixty-five HBV DNA positive pulmonary tuberculosis patients were randomly divided into treatment group (n = 81) and control group (n = 85). The incidence of liver damage, the time of occurrence and the degree of injury in the two groups were observed, and the data were statistically analyzed. Results: The incidence of hepatic injury in the treatment group was low (18.5%), with late onset (30-150) d, light liver damage and rapid recovery (17 ± 3.8) days. The time to complete anti-TB treatment was relatively short (210 ± 16.3 ) d, compared with the control group, the difference was significant (P <0.01). Conclusion: Entecavir has a significant intervention on liver function in patients with HBV DNA-positive pulmonary tuberculosis, which can significantly reduce the liver damage caused by tuberculosis drugs in these patients.